Dovel Technologies has won two contracts from the Food and Drug Administration’s Center for Biologics Effectiveness and Research to help build an ecosystem of tools to support biologic product safety.
Dovel has been awarded under two separate 5-year indefinite-delivery, indefinite-quantity deals: one for data, tools and infrastructure for surveillance of biologics and one covering the development of new and innovative methods for automated reporting for CBER-regulated biological products.
Dovel secured one of four awards for each of the IDIQs. Each award has a ceiling of $75 million.
“We are excited to get to work helping build the data strategy and tools that will enhance CBER’s efficiency in meeting their mission to assure the safety and efficacy of biologic products,” said Damon Griggs, Dovel president and chief operating officer. “Our team has exciting and innovative approaches and solutions for data science and automation using machine learning, natural language processing, and more to meet the needs of CBER.”
The center’s Biologics Effectiveness and Safety, or BEST, initiative aims to expand and enhance current capabilities with respect to data sources, infrastructure, methods and tools and to conduct active surveillance, epidemiologic studies and automated reporting to improve the the safety and efficacy of biologic products including vaccines, blood and blood products, tissues, and advanced therapeutics.